Next Article in Journal
Ubiquitin Pathway and Ovarian Cancer
Previous Article in Journal
Extended Adjuvant Temozolomide with cis-Retinoic Acid for Adult Glioblastoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 6
10.3747/co.19.1173
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada

by
W. Hanna
1,2,*,
P. Barnes
3,
R. Berendt
4,
M. Chang
1,5,
A. Magliocco
6,
A.M. Mulligan
1,7,
H. Rees
8,
N. Miller
1,9,
L. Elavathil
10,
B. Gilks
11,
N. Pettigrew
12,
D. Pilavdzic
13 and
S. SenGupta
14
1
University of Toronto, Toronto, ON, Canada
2
Sunnybrook and Women’s College Health Science Centre, University of Toronto, ON, Canada
3
QEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada
4
Cross Cancer Institute, Edmonton, AB, Canada
5
Mount Sinai Hospital, Toronto, ON, Canada
6
H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33682, USA
7
Toronto General Hospital, University Health Network, Toronto, ON, Canada
8
Saskatoon City Hospital, Saskatoon, SK, Canada
9
University Health Network, Toronto, ON, Canada
10
Juravinski Hospital and Cancer Centre, Mc-Master University, Hamilton, ON, Canada
11
Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada
12
University of Manitoba, Winnipeg, MB, Canada
13
McGill University, Montreal, QC, Canada
14
Queen’s University, Kingston, ON, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(6), 315-323; https://doi.org/10.3747/co.19.1173
Submission received: 6 September 2012 / Revised: 4 October 2012 / Accepted: 2 November 2012 / Published: 1 December 2012

Abstract

This review is designed to highlight several key challenges in the diagnosis of human epidermal growth factor receptor 2 (HER2)–positive breast cancer currently faced by pathologists in Canada: (1) Pre-analysis issues affecting the accuracy of HER2 testing in non-excision sample types: core-needle biopsies, effusion samples, fine-needle aspirates, and bone metastases (2) HER2 testing of core-needle biopsies compared with surgical specimens (3) Criteria for retesting HER2 status upon disease recurrence. Literature searches for each topic were carried out using the MEDLINE, Embase, International Pharmaceutical Abstracts, and biosis databases. In addition, the congress databases of the American Society of Clinical Oncology (2005–2011) and the San Antonio Breast Cancer Symposium (2007–2011) were searched for relevant abstracts. All authors are expert breast pathologists with extensive experience of HER2 testing, and several participated in the development of Canadian HER2 testing guidelines. For each topic, the authors present an evaluation of the current data available for the guidance of pathology practice, with recommendations for the optimization or improvement of HER2 testing practice.
Keywords: her2 testing; breast cancer; pathology her2 testing; breast cancer; pathology

Share and Cite

MDPI and ACS Style

Hanna, W.; Barnes, P.; Berendt, R.; Chang, M.; Magliocco, A.; Mulligan, A.M.; Rees, H.; Miller, N.; Elavathil, L.; Gilks, B.; et al. Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada. Curr. Oncol. 2012, 19, 315-323. https://doi.org/10.3747/co.19.1173

AMA Style

Hanna W, Barnes P, Berendt R, Chang M, Magliocco A, Mulligan AM, Rees H, Miller N, Elavathil L, Gilks B, et al. Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada. Current Oncology. 2012; 19(6):315-323. https://doi.org/10.3747/co.19.1173

Chicago/Turabian Style

Hanna, W., P. Barnes, R. Berendt, M. Chang, A. Magliocco, A.M. Mulligan, H. Rees, N. Miller, L. Elavathil, B. Gilks, and et al. 2012. "Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada" Current Oncology 19, no. 6: 315-323. https://doi.org/10.3747/co.19.1173

APA Style

Hanna, W., Barnes, P., Berendt, R., Chang, M., Magliocco, A., Mulligan, A. M., Rees, H., Miller, N., Elavathil, L., Gilks, B., Pettigrew, N., Pilavdzic, D., & SenGupta, S. (2012). Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada. Current Oncology, 19(6), 315-323. https://doi.org/10.3747/co.19.1173

Article Metrics

Back to TopTop